Please login to the form below

non-Hodgkin's lymphoma

This page shows the latest non-Hodgkin's lymphoma news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

CTI slumps as Servier-partnered lymphoma drug fails. After major setback CTI, has promising myelofibrosis candidate to fall back on. ... CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s

Latest news

Another R&D flop for Incyte, but Jakafi keeps delivering

Incyte is still trying to recover from the mauling it took after its IDO inhibitor epacadostat for cancer failed earlier this year, and yesterday wrote off another programme in
Bluebird and Celgene BCMA CAR-T kicks off ASCO

Celgene is also behind a presentation on day two of the show of new data from a pivotal trial lisocabtagene maraleucel ( JCAR017), a CAR-T for relapsed/refractory aggressive ... s lymphoma developed by Juno Therapeutics, which was acquired by Celgene
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

comparator EGFR inhibitors including Roche’s Tarceva (erlotinib) or AZ’s earlier-generation EGFR drug Iressa (gefitinib). ... s Carmubris (carmustine) for brain tumours, non-Hodgkin’s lymphoma and Hodgkin’s disease filed by Obvious Investment.
FDA turns down Celgene’s filing for multiple sclerosis drug

Celgene has had a difficult few months, with the latest knock coming after its blood cancer blockbuster Revlimid (lenalidomide) failed to hit the mark in non-Hodgkin’s lymphoma, the failure ... of Crohn’s disease candidate GED-0301, and lacklustre
CAR-T therapies show long-term benefits in lymphoma

CAR-T therapies show long-term benefits in lymphoma. Novartis’Kymriah and Gilead’s Yescarta both achieve significant complete response in lymphoma patients. ... One-year results from the ZUMA-1 trial of Gilead’s Yescarta (axicabtagene ciloleucel)

More from news
Approximately 15 fully matching, plus 111 partially matching documents found.

Latest Intelligence

Pharma deals during October 2014

Zykadia is approved in the US for patients with anaplastic lymphoma kinase (ALK) and metastatic NSCLC but not approved elsewhere; INC 280 and EFG 816 are in phase 1 development; the ... Hodgkin's lymphoma.
Interview: Kay Drake and Naoki Okamura, Astellas

The company has also out-licensed a non-small cell lung cancer treatment (Tarceva) and non-Hodgkin's lymphoma treatment (bendamustine) to its strategic partners, with several prospective new oncology medications ... So that's where we need the diversity,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Charles Morris appointed chief development officer at ImmunoGen

Immunogen has appointed Dr Charles Morris as the company's chief development officer. ... cancers that over-express folate receptor 1, and IMGN529 - in phase I testing for the treatment of non-Hodgkin's lymphoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer
Therapy Watch expands its oncology portfolio

Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal
Oncology drugs under AMNOG

Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial ... against ‘ treatment of physician’ s